Literature DB >> 16954596

Changes in the expression of G protein-coupled receptor kinases and beta-arrestins in mouse brain during cannabinoid tolerance: a role for RAS-ERK cascade.

Tiziana Rubino1, Daniela Viganò, Fabrizio Premoli, Chiara Castiglioni, Silvia Bianchessi, Renata Zippel, Daniela Parolaro.   

Abstract

The focus of our study was to determine the role of G protein-coupled receptor kinases (GRKs) and beta-arrestins in agonist-induced CB1 receptor modulation during cannabinoid tolerance and their dependence from the extracellular signal-regulated kinase (ERK) cascade. In wild-type mice, chronic Delta9-tetrahydrocannabinol (THC) exposure significantly activated specific GRK and beta- arrestin subunits in all the considered brain areas (striatum, cerebellum, hippocampus, and prefrontal cortex), suggesting their involvement in the adaptive processes underlying CB1 receptor downregulation and desensitization. These events were ERK-dependent in the striatum and cerebellum, because they were prevented in the genetic (Ras-GRF1 knockout mice) and pharmacological (SL327-pretreated mice) models of ERK activation inhibition, whereas in the hippocampus and prefrontal cortex, they appeared to be mostly ERK-independent. In the latter areas, ERK activation after chronic THC increased the transcription factors cyclic adenosine monophosphate response element-binding protein and Fos B as well as a downstream protein known as brainderived neurotrophic factor. As a whole, our data suggest that in the striatum and cerebellum, THC-induced ERK activation could represent a key signaling event to initiate homologous desensitization of CB1 receptor, accounting for the development of tolerance to THC-induced hypolocomotion. In the prefrontal cortex and hippocampus, THC-induced alteration in GRKs and beta-arrestins primarily depends on other kinases, whereas ERK activation could be part of the molecular adaptations that underlie the complex behavioral phenotype that defines the addicted state.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16954596     DOI: 10.1385/MN:33:3:199

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.682


  36 in total

1.  The MAPK cascade is required for mammalian associative learning.

Authors:  C M Atkins; J C Selcher; J J Petraitis; J M Trzaskos; J D Sweatt
Journal:  Nat Neurosci       Date:  1998-11       Impact factor: 24.884

2.  Synaptic secretion of BDNF after high-frequency stimulation of glutamatergic synapses.

Authors:  M Hartmann; R Heumann; V Lessmann
Journal:  EMBO J       Date:  2001-11-01       Impact factor: 11.598

3.  Neurotrophin-induced modulation of synaptic transmission in the adult hippocampus.

Authors:  H J Kang; E M Schuman
Journal:  J Physiol Paris       Date:  1995

4.  Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization.

Authors:  W Jin; S Brown; J P Roche; C Hsieh; J P Celver; A Kovoor; C Chavkin; K Mackie
Journal:  J Neurosci       Date:  1999-05-15       Impact factor: 6.167

5.  Time course for the induction and maintenance of tolerance to Delta(9)-tetrahydrocannabinol in mice.

Authors:  C E Bass; B R Martin
Journal:  Drug Alcohol Depend       Date:  2000-08-01       Impact factor: 4.492

6.  The role of several kinases in mice tolerant to delta 9-tetrahydrocannabinol.

Authors:  Matthew C Lee; Forrest L Smith; David L Stevens; Sandra P Welch
Journal:  J Pharmacol Exp Ther       Date:  2003-02-11       Impact factor: 4.030

7.  Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus.

Authors:  A Figurov; L D Pozzo-Miller; P Olafsson; T Wang; B Lu
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

8.  Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study.

Authors:  A Oviedo; J Glowa; M Herkenham
Journal:  Brain Res       Date:  1993-07-09       Impact factor: 3.252

9.  Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol.

Authors:  J Romero; L García; J J Fernández-Ruiz; M Cebeira; J A Ramos
Journal:  Pharmacol Biochem Behav       Date:  1995-08       Impact factor: 3.533

10.  Modulation of extracellular signal-regulated kinases cascade by chronic delta 9-tetrahydrocannabinol treatment.

Authors:  Tiziana Rubino; Greta Forlani; Daniela Viganò; Renata Zippel; Daniela Parolaro
Journal:  Mol Cell Neurosci       Date:  2004-03       Impact factor: 4.314

View more
  32 in total

Review 1.  Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?

Authors:  Tricia H Smith; Laura J Sim-Selley; Dana E Selley
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

2.  Molecular Interaction between Distal C-Terminal Domain of the CB1 Cannabinoid Receptor and Cannabinoid Receptor Interacting Proteins (CRIP1a/CRIP1b).

Authors:  Pratishtha Singh; Anjali Ganjiwale; Allyn C Howlett; Sudha M Cowsik
Journal:  J Chem Inf Model       Date:  2019-12-10       Impact factor: 4.956

3.  Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by l-DOPA treatment.

Authors:  M Rafiuddin Ahmed; Evgeny Bychkov; Vsevolod V Gurevich; Jeffrey L Benovic; Eugenia V Gurevich
Journal:  J Neurochem       Date:  2007-11-07       Impact factor: 5.372

4.  Age-dependent role for Ras-GRF1 in the late stages of adult neurogenesis in the dentate gyrus.

Authors:  Michael J Darcy; Stéphanie Trouche; Shan-Xue Jin; Larry A Feig
Journal:  Hippocampus       Date:  2014-03       Impact factor: 3.899

5.  Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans.

Authors:  Deepak Cyril D'Souza; Brian Pittman; Edward Perry; Arthur Simen
Journal:  Psychopharmacology (Berl)       Date:  2008-09-21       Impact factor: 4.530

Review 6.  G protein-coupled receptor kinases: more than just kinases and not only for GPCRs.

Authors:  Eugenia V Gurevich; John J G Tesmer; Arcady Mushegian; Vsevolod V Gurevich
Journal:  Pharmacol Ther       Date:  2011-08-26       Impact factor: 12.310

7.  Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models.

Authors:  Eric A Horne; Jonathan Coy; Katie Swinney; Susan Fung; Allison E T Cherry; William R Marrs; Alipi V Naydenov; Yi Hsing Lin; Xiaocui Sun; C Dirk Keene; Eric Grouzmann; Paul Muchowski; Gillian P Bates; Ken Mackie; Nephi Stella
Journal:  Eur J Neurosci       Date:  2012-11-21       Impact factor: 3.386

Review 8.  Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.

Authors:  Ryan Wyrofsky; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Expert Opin Drug Discov       Date:  2014-12-09       Impact factor: 6.098

Review 9.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

10.  Delta FosB and AP-1-mediated transcription modulate cannabinoid CB₁ receptor signaling and desensitization in striatal and limbic brain regions.

Authors:  Matthew F Lazenka; Bethany G David; Aron H Lichtman; Eric J Nestler; Dana E Selley; Laura J Sim-Selley
Journal:  Biochem Pharmacol       Date:  2014-08-02       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.